Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

NCT03600805 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

83

Enrollment

INDUSTRY

Sponsor class

Stopped Protracted recruitment timeline exacerbated by COVID-19 pandemic

Conditions

Giant Cell Arteritis

Interventions

DRUG: Sarilumab SAR153191
DRUG: Sarilumab matching placebo
DRUG: Prednisone
DRUG: Prednisone matching placebo

Sponsor

Sanofi

Collaborators

[object Object]